Study	Region	Study design	Date	Total patients	Recruitment of participants	Diagnosis of SARS- CoV-2 infection	AST (IU/L)	ALT (IU/L)	Total bilirubin (μmol/L)	Average age (years)	Female (%)	Percentage of outpatient, general inpatient, ICU admission	History of liver disease (%)
Huang et al ¹	Wuhan	Case- series	Publication: 1/24/20 Study: 12/16/19 – 1/2/20	41	Patients with laboratory- confirmed 2019-nCoV infection were enrolled from Jin Yintan Hospital in Wuhan, China.	2019-nCoV infection was confirmed by real- time RT- PCR and next- generation sequencing.	Overall: 34.0 ≤40: 63.0% >40: 37.0% ICU: 44.0 ≤40: 38.0% >40: 62.0% Non- ICU: 34.0 ≤40: 75.0% >40: 25.0%	Overall: 32.0 ICU: 49.0 Non-ICU: 27.0	Overall: 11.7 ICU: 14.0 Non-ICU: 10.8	Overall: 49.0 ICU: 49.0 Non-ICU: 49.0	Overall: 27.0 ICU: 15.0 Non- ICU: 32.0	ICU: 31.7 Non-ICU: 68.3	Overall: 2.0 ICU: 0 Non-ICU: 4.0
Chen et al ²	Wuhan	Case- series	Publication: 1/29/20 Study: 1/1/20– 1/20/20	99	Patients with laboratory- confirmed 2019-nCoV infection were enrolled from Jin Yintan Hospital in Wuhan, China.	2019-nCoV infection was confirmed by real- time RT- PCR and next- generation sequencing.	Overall: 34.0 ≤40: 65.0% >40: 35.0%	Overall: 39.0 ≤50: 72.0% >50: 28.0%	Overall: 15.1 ≤21: 82.0% >21: 18.0%	Overall: 55.5 ±13.1	Overall: 32.0	ICU: 23.0 Non-ICU: 77.0	Overall: Digestive system disease 11.0
Chen et al ³	Wuhan	Case- series	Publication: 2/6/20 Study: 1/20	29	Patients with laboratory- confirmed 2019-nCoV	2019-nCoV infection was confirmed	≤40: 76.0% >40: 24.0%	≤41: 83.0% >41: 17.0%	≤26: 97.0% >26: 3.0%	Overall: 56.0	Overall: 79.0	NA	NA

Supplementary Table 1. Characteristics of Studies Included in the Meta-analysis.

					infection were enrolled from Tongji Hospital in Wuhan, China.	by real- time RT- PCR.							
Wang et al ⁴	Wuhan	Case- series	Publication: 2/7/20 Study: 1/1/20- 1/28/20	138	Patients with laboratory- confirmed 2019-nCoV- infected pneumonia were enrolled from Zhongnan hospital.	2019-nCoV infection was confirmed by real- time RT- PCR and next- generation sequencing.	Overall: 31.0 ICU: 52.0 Non- ICU: 29.0	Overall: 24.0 ICU: 35.0 Non-ICU: 23.0	Overall: 9.8 ICU: 11.5 Non-ICU: 9.3	Overall: 56.0 ICU: 66.0 Non-ICU: 51.0	Overall: 63.0 ICU: 14.0 Non- ICU: 49.0	ICU: 26.1 Non-ICU: 73.9	Overall: 2.9 ICU: 0 Non-ICU: 3.9
Liu et al ⁵	Shenzh en	Case- series	Publication: 2/9/20 Study: 1/21/20	12	Patients with laboratory- confirmed 2019-nCoV- infected pneumonia, aged 10-72 years, were enrolled from Shenzhen Third People's hospital.	2019-nCoV infection was confirmed by real- time RT- PCR.	Overall: 40.0 ≤45: 83.3% >45: 16.7%	Overall: 31.6 ≤45: 83.3% >45: 16.7%	Overall: 8.9 ≤22: 100.0% >22:0%	Overall: 53.7	Overall : 33.3	NA	Overall: 0
Chen et al ⁶	Wuhan	Case- series	Publication: 2/12/20 Study: 1/20/20- 1/31/20	9	Pregnant patients with laboratory- confirmed 2019-nCoV- infected pneumonia, aged 26-40 years, were	2019-nCoV infection was confirmed by quantitativ e RT-PCR.	Overall: 171.0 ≤35: 66.7% >35: 33.3%	Overall: 253.8 ≤45: 66.7% >45: 33.3%	NA	Overall: 29.9	Overall: 100.0	NA	NA

Xu et al ⁷	Zhejian g	Case- series	Publication: 2/13/20 Study: 1/10/20- 1/26/20	62	enrolled from Zhongnan Hospital of Wuhan University Patients with laboratory- confirmed 2019-nCoV- infection, aged 10 years and older, were enrolled from seven	2019-nCoV infection was confirmed by real- time RT- PCR.	<40: 83.9% ≥40: 16.1%	Overall: 22.0	NA	Overall: 41.0	Overall 43.5	ICU: 1.6 Non-ICU: 98.4	Overall: 11.3
Yao et al ⁸	Shaanxi	Case- series	Publication: 2/20/20 Study: 2/21/20- 2/21/20	40	hospitals in Zhejiang province. Patients with laboratory- confirmed 2019-nCoV- infection, aged 22-83 years, were enrolled from Tangdu Hospital.	2019-nCoV infection was confirmed by real- time RT- PCR.	Combine d AST (>46) and ALT elevatio n: 40.0%	≤66: 47.5% >66: 52.5%	≤20.5: 75% >20.5: 25.0%	Overall: 53.9	Overall: 40.0 Abnor mal liver functio n: 36.4 Normal liver functio n: 42.9	Severe case with abnormal liver function: 77.3 Severe case with normal liver function: 27.8	Overall: 5.0
Yang et al ⁹	Wuhan	Case- series	Publication: 2/21/20 Study: 12/24/19- 1/26/20	52	Critically III patients who admitted to ICU with laboratory- confirmed 2019-nCoV- infected pneumonia were enrolled	2019-nCoV infection was confirmed by real- time RT- PCR or next- generation sequencing.	Overall liver dysfuncti on (ICU): 28.8% Liver dysfuncti on in survivor (ICU): 30.0%	Overall liver dysfuncti on (ICU): 28.8% Liver dysfuncti on in survivor (ICU): 30.0%	Overall total bilirubin in survivor (ICU): 13.2 Overall total bilirubin in non-	Overall: 59.7 Survivor: 51.9 Non- survivor: 64.6	Overall: 32.7 Survivo r: 30.0 Non- survivor : 34.4	ICU: 100.0 Non-ICU: 0 Survivor: 38.5 Non- survivor: 61.5	NA

					from Jin Yin- tan hospital.		Liver dysfuncti on in non- survivor (ICU): 28.0%	Liver dysfuncti on in non- survivor (ICU): 28.0%	survivor (ICU): 19.5				
Lei et al ¹⁰	Chongq ing	Case- series	Publication: 2/23/20 Study: 1/20/20- 2/3/20	51	Patients with laboratory- confirmed 2019-nCoV infection were enrolled from Chongqing University Three Gorges Hospital and were followed up until 2/11/20.	2019-nCoV infection was confirmed by RT-PCR.	Overall: 21.0 Non- severe: 21.0 Severe: 29.0	Overall: 18.0 Non- severe: 18.0 Severe: 26.0	NA	Overall: 45.0 Severe: 52.0 Non- severe: 44.0	Overall: 37.3 Severe: 42.9 Non- severe: 36.4	NA	Severe Hepatitis B: 2.0
Shi et al ¹¹	Wuhan	Case- series	Publication: 2/24/20 Study: 12/20/19- 1/23/20	81	Patients with laboratory- confirmed 2019-nCoV- infected pneumonia were enrolled from Jinyintan or Tongji hospital.	2019-nCoV infection was confirmed by real- time RT- PCR or next- generation sequencing.	Overall: 40.8 ≤40: 47.0% >40: 53.0%	Overall: 46.2	Overall: 11.9	Overall : 49.5 ± 11.0	Overall: 48.0	NA	Overall: 9.0
Cao et al ¹²	Hubei	Case- series	Publication: 2/25/20 Study: 1/1/20- 2/16/20	128	Patients with laboratory- confirmed 2019-nCoV were enrolled	2019-nCoV infection was confirmed by real-	Overall: 30.6 Non- severe: 28.0	Overall: 31.4 Non- severe: 28.9	NA	Overall: NA	Overall: 53.1 Non- severe: 55.1	NA	NA

None et	Zhaiian	Gase	Dublication	140	from Xiangyang Number One hospital.	time RT- PCR. 2019-nCoV	Severe: 44.0	Severe: 43.9	Querelli	Querelli	Severe: 42.9	Conord	Quantil
Yang et al ¹³	Zhejian g	Case- series	Publication: 2/26/20 Study: 1/17/20- 2/10/20	149	Patients with laboratory- confirmed 2019-nCoV infection were enrolled from three tertiary hospitals of Wenzhou.	infection was confirmed by real- time RT- PCR.	Overall: 23.0 ≤40: 81.9% >40: 18.1%	Overall: 20.0 ≤64: 87.9% >64: 12.1%	Overall: 9.9 ≤24: 97.3 >24:2.7%	Overall: 45.1	Overall : 45.6	General inpatient: 100.0	Overall digestive system disease: 5.4
Huang et al ¹⁴	Wuhan	Case- series	Publication: 2/27/20 Study: 12/21/19- 1/28/20	34	Patients with laboratory- confirmed 2019-nCoV infection, aged 26-88 years, were enrolled from Zhongnan hospital and were followed up until 1/29/20.	2019-nCoV infection was confirmed by real- time RT- PCR.	Overall elevated : 20.6% Overall normal: 79.4%	Overall elevated: 23.5% Overall normal: 76.5%	Overall elevated: 8.8% Overall normal: 91.2%	Overall: 56.2	Overall: 58.8	ICU: 23.5 General inpatient: 76.5	Overall: 2.9
Fan et al ¹⁵	Shangh ai	Case- series	Publication: 2/28/20 Study: 1/20/20- 1/31/20	148	Patients with laboratory- confirmed 2019-nCoV infection, aged 15-88 years, were enrolled from Shanghai Public Health	2019-nCoV infection was confirmed by real- time RT- PCR.	≤35: 78.4% >35: 21.6%	≤40: 81.8% >40: 18.2%	≤20.5: 93.9% >20.5: 6.1%	Overall: 50.0	Overall: 50.7	NA	Overall : 5.4 Abnormal liver function: 4.0 Normal liver function: 1.4

					Clinical Center, and were followed up until 2/19/20.								
Guan et al ¹⁶	China	Case- series	Publication: 2/28/20 Study: 12/11/19- 1/31/20	1,099	Patients with laboratory- confirmed 2019-nCoV were enrolled from 552 hospitals in 30 provinces, autonomous regions and municipalitie s in China.	2019-nCoV infection was confirmed by sequencing or real-time RT-PCR.	≤40: 77.8% >40: 22.2%	≤40: 78.7% >40: 21.3%	≤17.1: 89.5% >17.1: 10.5%	Overall: 47.0	Overall: 41.9	ICU: 5.0 Non-ICU: 95.0	Overall: Hepatitis B infection 2.1
Liu et al ¹⁷	Wuhan	Case- series	Publication: 2/28/20 Study: 12/30/19- 1/15/20	78	Patients with laboratory- confirmed 2019-nCoV infected pneumonia were enrolled from three tertiary hospitals in Wuhan.	2019-nCoV infection was confirmed by real- time RT- PCR.	Overall: 20.5	Overall: 18.1	NA	Overall: 38.0 Improve ment/sta bilization group: 37.0 Progressi on group: 66.0	Overall: 50.0 Improv ement/ stabiliza tion group: 52.5 Progres sion group: 36.4	General inpatient: 100.0	NA
Wu et al ¹⁸	Jiangsu	Case- series	Publication: 2/29/20 Study: 1/22/20- 2/14/20	80	Patients with laboratory- confirmed 2019-nCoV were enrolled from the three hospital in	2019-nCoV infection was confirmed by real- time RT- PCR.	Overall: 30.0 ≤39: 96.2% >39:3.8 %	Overall: 24.0 ≤38: 96.2% >38:3.8%	Overall: 6.6 ≤12: 98.8% >12: 1.2%	Overall : 46.1 ± 15.4	Overall : 51.3	NA	Overall: Chronic liver disease: 1.3 Digestive system disease: 1.3

					Jiangsu province.								
Zhang et al ¹⁹	Beijing	Case- series	Publication: 3/4/20 Study: NA	56	Patients with laboratory- confirmed 2019-nCoV were enrolled from the Fifth Medical Center of PLS General Hospital in Beijing.	2019-nCoV infection was confirmed by real- time RT- PCR.	Overall: 28.6	NA	NA	NA	NA	NA	Overall: 3.6
Zhou et al ²⁰	Wuhan	Case- series	Publication: 3/9/20 Study: 12/29/19- 1/31/20	191	Patients with laboratory- confirmed 2019-nCoV- infection, aged 18-87 years, were enrolled from Jinyintan hospital and Wuhan Pulmonary hospital.	2019-nCoV infection was confirmed by real- time RT- PCR or next- generation sequencing.	NA	Overall: 30.0 Survivor: 27.0 Non- survivor: 40.0 ≤40: 68.8% >40: 31.2%	NA	Overall: 56.0 Survivor: 52.0 Non- survivor: 69.0	Overall: 37.7 Survivo r: 40.9 Non- survivor :29.6	General inpatient: 73.8 ICU: 26.2	NA
Li et al ²¹	Beijing	Case- series	Publication: 3/10/20 Study: 1/21/20- 2/29/20	85	Patients with laboratory- confirmed 2019-nCoV infection were enrolled from Beijing You'an hospital.	2019-nCoV infection was confirmed by real- time RT- PCR.	Overall: 29.0 Combine d AST and ALT elevatio n: 38.8%	Overall: 28.0 Elevated ALT: 38.8% Normal ALT: 61.2%	Overall: 9.2 Elevated ALT: 11.8 Normal ALT: 8.7	Overall: 49.0 ALT elevation group: 59.0 ALT normal group: 44.5	Overall: 9.2 ALT elevatio n group: 54.5 ALT normal group: 57.7	NA	Overall : 7.0 ALT elevation group: 9.1 ALT normal group: 5.8
Zhao et al ²²	Anhui	Case- control study	Publication: 3/12/20 Study:	34 (19 cases with positive	Cases were laboratory- confirmed	2019-nCoV infection was	Case: 34.9	Case: 36.4 ≤50: 72.2	NA	Case: 48.0	Case: 42.1	NA	Case: 5.3 Control: 0

			1/23/20- 2/5/20	2019- nCoV and 15	2019-nCoV- infected pneumonia	confirmed by real- time RT-	≤40: 72.2 >40:	>50:27.8 Control:		Control: 35.0	Control: 60.0		
				controls with negative 2019- nCoV)	enrolled from Second Affiliated Hospital of Anhui Medical University and Suzhou Municipal Hospital.	PCR.	27.8 Control: 21.3 ≤40: 100.0 >40: 0	21.4 ≤50: 100.0 >50:0					
					Controls were laboratory- confirmed 2019-nCoV- negative pneumonia enrolled from the same hospital.								
Zhou et al ²³	Wuhan	Case- series	Publication: 3/12/20 Study: 12/20/19- 2/9/20	254	Patients with clinically confirmed 2019-nCoV- infected pneumonia were enrolled from the central hospital of Wuhan.	2019-nCoV infection was diagnosed based on clinical criteria of NCIP.	Medical staff GI sympto ms: 26.4 Non-GI sympto ms: 40.4 Non- medical staff GI sympto ms: 47.8 Non-GI sympto ms: 53.8	Medical staff GI sympto ms: 65.9 Non-GI sympto ms: 75.6 Non- medical staff GI sympto ms: 64.1 Non-GI sympto ms: 46.6	NA	Overall: 50.6	Overall: 54.7	NA	Overall: 1.2 Medical staff GI symptoms: 0 Non-GI symptoms: 1.0 Non- medical staff GI symptoms: 0

													Non-GI symptoms: 2.0
Wu et al ²⁴	Wuhan	Case- series	Publication: 3/13/20 Study: 12/25/19- 2/13/20	198	Patients with laboratory- confirmed 2019-nCoV- infected pneumonia who were admitted in Wuhan Jinyintan Hospital during December 25, 2019 and January 26, 2020 and follow up until February 13, 2020.	2019-nCoV infection was confirmed by real- time RT- PCR.	Overall: 33.0 ≤40: 70.2% >40: 29.8%	Overall: 31.0 ≤40: 78.3% >40: 21.7%	Overall: 11.45 mg/dL ≤14.75: 94.9% >14.75: 5.1%	Overall: 51.0	Overall : 36.3	ICU: 26.4 Non-ICU: 73.6	Overall: 3.5
Zhu et al ²⁵	Anhui	Cross- sectional study	Publication: 3/13/20 Study: 1/24/20- 2/20/20	116 (32 patients with positive 2019- nCoV and 84 patients with negative 2019- nCoV)	Cross- sectional study of patients with clinically suspicious of 2019-nCoV who got laboratory testing at two emergency departments in Anhui	2019-nCoV infection was confirmed by RT-PCR. Test was repeated after 24 hours if the first test was negative.	Positive 2019- nCoV: 31.1 Negative 2019- nCoV: 23.7	Positive 2019- nCoV: 30.1 Negative 2019- nCoV: 23.3	NA	Positive 2019- nCoV: 46.0 Negative 2019- nCoV: 35.0	Positive 2019- nCoV: 53.1 Negativ e 2019- nCoV: 54.0	NA	Positive 2019-nCoV: 6.3 Negative 2019-nCoV: 3.6
Lo et al ²⁶	Macau	Case- series	Publication: 3/15/20 Study:	10	Patients with laboratory- confirmed 2019-nCoV	2019-nCoV infection was confirmed	Overall: 20.0 Mild to moderat	Overall: 24.0 Elevated AST or	Overall : 6.0	Overall : 54.0	Overall: 70.0	General inpatient: 100.0	Overall: 10.0

			1/21/20- 2/16/20		infection, aged 15 years and above, were enrolled from Centro Hospitalar Conde de São Januário in Macau.	by real time RT-PCR.	e group: 19.0 Severe group: 24.0 Elevated AST or ALT: 20.0%	ALT: 20.0%					
Mo et al ²⁷	Wuhan	Case- series	Publication: 3/16/20 Study: 1/1/20- 2/5/20	155	Patients with laboratory- confirmed 2019-nCoV- infected pneumonia were enrolled from Zhongnan hospital	2019-nCoV infection was confirmed by virus nucleic acid detection kit.	Overall: 32.0 General group: 32.0 Refracto ry group: 37.0	Overall: 23.0 General group: 20.0 Refracto ry group: 28.0	NA	Overall: 54.0 General group: 46.0 Refracto ry group: 61.0	Overall: 44.5 General group: 55.6 Refract ory group: 35.3	NA	Overall: 4.5 General group: 2.9 Refractory group: 5.9
Gao et al ²⁸	Fuyang	Case- series	Publication: 3/17/20 Study: 1/23/20- 2/2/20	43	Patients with laboratory- confirmed 2019-nCoV infection, aged 19-70 years, were enrolled from Fuyang Second people's hospital.	2019-nCoV infection was confirmed by real time RT-PCR.	Severe group: 27.8 Mild group: 33.2	Severe group: 27.0 Mild group: 24.5	NA	Overall: 43.7 Severe group: 45.2 Mild group: 43.0	Overall: 39.5 Severe group: 40.0 Mild groups: 39.3	NA	NA
Jin et al ²⁹	Zhejian g	Case- series	Publication: 3/17/20 Study: 1/17/20- 2/8/20	651	Patients with laboratory- confirmed 2019-nCoV with gastrointesti nal symptoms (nausea,	2019-nCoV infection was confirmed by real- time RT- PCR.	GI sympto ms: 29.4 No GI sympto ms: 24.4 Liver injury	GI sympto ms: 25.0 No GI sympto ms: 21.5	GI sympto ms: 10.0 No GI sympto ms: 9.6	Overall : 46.1 GI sympto ms: 46.1 ± 14.2 No GI sympto	Overall: 50.0 Gl sympto ms: 50.0 No Gl sympto	ICU: GI symptoms: 6.8 No GI symptoms: 2.1 Non-ICU:	GI symptoms: 10.8 No GI symptoms: 3.0

					vomiting or diarrhea) were enrolled. Data were collected by the Health Commission of Zhejiang Province in designated hospitals.		(AST> 40 or ALT > 50) GI sympto ms: 17.6% No GI sympto ms: 8.8%			ms: 45.1 ± 14.5	ms: 50.0	GI symptoms: 93.2 No GI symptoms: 97.9	
Qian et al ³⁰	Zhejian g	Case- series	Publication: 3/17/20 Study: 1/20/20- 2/11/20	91 (88 patients with laborator y- confirmed 2019- nCoV and 3 cases with clinical- confirmed 2019- nCoV)	Patients with laboratory- confirmed and clinical- confirmed 2019-nCoV infection, aged 5-96 years, were enrolled from five hospitals in Zhejiang.	2019-nCoV infection was confirmed by real- time RT- PCR, clinical symptoms and chest CT findings.	Overall: 21.0 ≤40: 90.1% >40: 9.9% Severe group: 27.0 Mild group: 21.0	Overall: 18.0 ≤50: 92.3% >50: 7.7% Severe group: 19.9 Mild group: 18.0	NA	Overall: 50.0 Severe group: 66.0 Mild group: 49.0	Overall: 59.3	ICU: 9.9 Non-ICU: 90.1	NA
Luo et al ³¹	Wuhan	Case- series	Publication: 3/18/20 Study: 1/1/20- 2/20/20	183	Patients with laboratory- confirmed 2019-nCoV with gastrointesti nal symptoms who admitted in Zhongnan Hospital of Wuhan University were enrolled.	2019-nCoV infection was confirmed by real- time RT- PCR.	GI sympto ms: 65.8 ± 12.7	GI sympto ms: 66.4 ± 13.2	NA	Overall: 53.8	Overall: 44.0	NA	NA

Pan et al ³²	Wuhan	Case- series	Publication: 3/18/20 Study: 1/18/20- 2/28/20	201	Patients with laboratory- confirmed 2019-nCoV who admitted from 3 hospitals in Hubei province including Wuhan Hanan, Wuhan Union, and Huanggang Central hospital were enrolled.	2019-nCoV infection was confirmed by real- time RT- PCR.	Overall: 31.4 GI sympto ms: 35.1 No GI sympto ms: 27.5	Overall: 36.0 GI sympto ms: 42.2 No GI sympto ms: 29.5	Overall: 13.7 mmol/L GI sympto ms: 13.8 mmol/L No GI sympto ms: 13.5 mmol/L	Overall: 52.9 ± 16.0 GI sympto ms: 52.2 ± 15.9 No GI sympto ms: 53.6 ± 16.0	Overall: 47.5 GI sympto ms: 46.6 No GI sympto ms: 48.5	Overall: 7.8 Gl symptoms: 5.9 No Gl symptoms: 9.9	Overall Digestive system diseases: 3.4 GI symptoms: 3.9 No GI symptoms: 3.0
Wan et al ³³	Northe ast Chongq ing	Case- series	Publication: 3/18/20 Study: 1/23/20- 2/8/20	135	Patients with laboratory- confirmed 2019-nCoV- infection who admitted to the Chongqing University Three Gorges Hospital were enrolled.	2019-nCoV infection was confirmed by real- time RT- PCR.	Overall: 33.4 ≤40: 77.8 >40: 22.2 Mild cases: 22.4 ≤40: 84.0 >40: 16.0 Severe cases: 33.6 ≤40: 62.5 >40: 37.5	Overall: 26.0 Mild cases: 21.7 Severe cases: 26.6	Overall: 8.6 Mild cases: 8.6 Severe cases: 9.8	Overall: 47.0 Mild cases: 44.0 Severe cases: 56.0	Overall: 46.7 Mild cases: 45.3 Severe cases: 47.5	Overall: 1.5 Mild cases: 1.0 Severe cases: 2.5	NA
Arentz et al ³⁴	Washin gton	Case- series	Publication: 3/19/20	21	Patients with laboratory-	2019-nCoV infection	Overall (ICU):	Overall (ICU):	Overall (ICU):	Overall : 70.0	Overall : 48.0	ICU : 100.0 Non- ICU : 0	NA

			Study: 2/20/20- 3/2/20		confirmed 2019-nCoV- infection who admitted to ICU at Evergreen hospital were enrolled.	was confirmed by real- time RT- PCR.	273.0	108.0	0.6 mg/dL				
Chen et al ³⁵	Shangh ai	Case- series	Publication: 3/19/20 Study: 1/20/20- 2/6/20	249	Patients with laboratory- confirmed 2019-nCoV- infection were enrolled from Shanghai Public Health Clinical Center and were followed up until 2/25/20	2019-nCoV infection was confirmed by real- time RT- PCR for SARS-CoV- 2.	Overall: 25.0	Overall: 23.0	NA	Overall: 51.0	Overall: 49.4	ICU: 8.8 Non-ICU: 91.2	NA
Su et al ³⁶	Jinan	Case- series	Publication: 3/20/20 Study: 1/24/20- 2/24/20	9	Children with laboratory- confirmed 2019-nCoV- infection who admitted to Jinan Infectious Diseases hospital were enrolled.	2019-nCoV infection was confirmed by real- time RT- PCR.	Overall: 32.0	Overall: 15.2	NA	Overall: 3.5	Overall : 66.7	NA	NA

Ye et al ³⁷	Wuhan	Case- series	Publication: 3/20/20 Study: 1/8/20- 2/10/20	5	Patients with laboratory- confirmed 2019-nCoV- pneumonia who admitted to Zhongnan hospital were enrolled.	2019-nCoV infection was confirmed by quantitativ e RT-PCR.	Overall: 21.2 Elevated AST: 0% Normal: 100.0%	Overall: 17.2 Elevated ALT: 0% Normal: 100.0%	NA	Overall: 32.4	Overall : 62.0	NA	NA
Zhang et al ³⁸	Zhejian g	Case- series	Publication: 3/20/20 Study: 1/17/20- 2/8/20	645	Patients with laboratory- confirmed 2019-nCoV- infection were enrolled from hospitals in Zhejiang province.	2019-nCoV infection was confirmed by real- time RT- PCR.	Normal imaging group: 25.7 ± 15.5 Abnorm al imaging group: 30.1 ± 20.4	Normal imaging group: 25.5 ± 20.0 Abnorma I imaging group: 29.4 ± 25.7	Normal imaging group: 9.1 ± 4.9 Abnorma I imaging group: 11.3 ± 8.0	Normal imaging group: 34.9 ± 14.2 Abnorma l imaging group: 46.7 ± 13.8	Normal imaging group: 54.2 Abnor mal imaging group: 48.5	Normal imaging group: ICU: 0% Non-ICU: 100.0% Abnormal imaging group: ICU: 0.7% Non-ICU: 99.3%	Normal imaging group: 2.8 Abnormal imaging group: 4.0
Deng et al ³⁹	Wuhan	Case- series	Publication: 3/20/20	225	Fatal and recovered patients with laboratory- confirmed 2019-nCoV- infection were enrolled from two tertiary hospitals in Wuhan.	2019-nCoV infection was confirmed by RT-PCR.	Death group: 34.0 Recover ed group: 22.0	Death group: 22.0 Recovere d group: 18.7	NA	Death group: 69.0 Recover ed group: 40.0	NA	NA	NA
Zhou et al ⁴⁰	Wuhan	Case- series	Publication: 3/21/20 Study: 2/5/20- 2/13/20	34	Patients with laboratory- confirmed severe and very severe	2019-nCoV infection was confirmed by real-	Severe: 32.0 Very severe: 44.0	Severe: 34.0 Very severe: 49.0	NA	Severe: 63.0 Very severe: 67.0	Severe: 53.8 Very severe: 37.5	NA	NA

					2019-nCoV- infection who admitted to the West District of Union hospital of Tongji Medical College were enrolled.	time RT- PCR.							
Tang et al ⁴¹	Wuhan	Case- control	Publication: 3/24/20 Study: 12/24/19- 2/7/20	148 (73 patients with laborator y- confirmed 2019- nCoV and 75 cases with influenza A H1N1 infection)	Patients with laboratory- confirmed 2019-nCoV- infection who admitted at Wuhan Pulmonary hospital were enrolled.	Presence of SARS-CoV-2 in sample from respiratory tract or blood	Overall: 25.5	Overall: 34.5	Overall: 9.8	Overall: 67.0	Overall: 38.4	NA	NA
Lian et al ⁴²	Zhejian g	Case- series	Publication: 3/25/20 Study: 1/17/20- 2/12/20	788	Patients with laboratory- confirmed 2019-nCoV- infection were enrolled from Zhejiang province.	2019-nCoV infection was confirmed by real- time RT- PCR.	Age<60: 24.0 Age≥60: 28.0	Age<60: 22.0 Age≥60: 21.0	Age<60: 9.5 Age≥60: 9.7	Age<60: 41.2±11. 4 Age≥60: 68.3±7.3	Age<60 :46.5 Age≥60 :57.4	Age<60: 9.6 Age≥60: 1.4	Age<60: 3.8 Age≥60: 4.4
Shi et al ⁴³	Wuhan	Case- series	Publication: 3/25/20 Study: 1/20/20- 2/10/20	416	Patients with laboratory- confirmed 2019-nCoV- infection admitted in	2019-nCoV infection was confirmed by real- time RT- PCR.	Overall: 30.0 With cardiac injury: 40.0	Overall: 28.0 With cardiac injury: 29.0	NA	Overall: 64.0 With cardiac injury: 74.0	Overall: 50.7 With cardiac injury: 46.3	NA	NA

					Renmin hospital.		No cardiac injury: 29.0	No cardiac injury: 28.0		No cardiac injury: 60.0	No cardiac injury: 51.8		
Zheng et al ⁴⁴	Wuhan	Case- series	Publication: 3/25/20 Study: 2/1/20- 2/10/20	25	Children aged 1 month – 14 years with laboratory- confirmed 2019-nCoV infection admitted in 10 public hospitals in Wuhan.	2019-nCoV infection was confirmed by real- time RT- PCR.	NA	Overall: 12.0	NA	Overall: 3.0	Overall: 44.0	NA	NA
Chen et al ⁴⁵	Wuhan	Case- series	Publication: 3/26/20 Study: 1/13/20- 2/28/20	274	Patients with laboratory- confirmed 2019-nCoV were enrolled from Tongji hospital.	2019-nCoV infection was confirmed by real- time RT- PCR.	Overall: 30.0 ≤40: 69.0% >40: 31.0% Deaths: 45.0 ≤40: 38.0% >40: 62.0% Recover ed: 25.0 ≤40: 48.0% >40: 52.0%	Overall: 23.0 ≤40: 78.0% >40: 22.0% Deaths: 28.0 ≤40: 73.0% >40: 27.0% Recovere d: 20.0 ≤40: 81.0% >40: 19.0%	Overall: 9.6 mmol/L Deaths: 12.6 mmol/L Recovere d: 8.4 mmol/L	Overall: 62.0 Death: 68.0 Recovere d: 51.0	Overall: 38.0 Death: 27.0 Recover ed: 45.0	NA	HBsAg positive Overall : 4.0 Deaths: 4.0 Recovered: 4.0 Gastrointes tinal disease: Overall : 1.0 Deaths: 1.0 Recovered: 1.0 Acute liver injury: Overall : 5.0 Deaths: 9.0 Recovered: 2.0
Zhang et al ⁴⁶	Wuhan	Case- series	Publication: 3/26/20 Study:	95	Patients with laboratory- confirmed 2019-nCoV-	2019-nCoV infection was confirmed	Overall <40: 52.6%	Overall <40: 45.3%	NA	Overall: 49.0	Overall: 44.2	NA	NA

Chen et al ⁴⁷	Wuhan	Case- series	1/16/20- 2/25/20 Publication: 3/27/20 Study: 12/2019- 1/27/20	21	infected pneumonia were enrolled from Wuhan Xinzhou District People's Hospital and were followed up until 3/2/20. Patients with laboratory- confirmed 2019-nCoV- infected pneumonia who were admitted at Tongji hospital.	by real- time RT- PCR. 2019-nCoV infection was confirmed by real- time RT- PCR.	40-80: 35.8% >80: 11.6% Non- severe: <40: 60.3% 40-80: 30.2% >80: 9.5% Severe: <40: 37.5% 40-80: 46.9% >80: 15.6% Overall: 27.0 ≤40: 71.4 >40: 28.6 Moderat e cases: 24.0 ≤40: 100.0 >40: 0 Severe cases: 47.0 ≤40: 54.5	40-80: 28.4% >80: 26.3% Non- severe: <40: 55.6% 40-80: 22.2% Severe: <40: 25.0% 40-80: 40.6% >80: 34.4% Overall: 26.0 Moderat e cases: 16.0 Severe cases: 42.0	Overall: 8.8 Moderat e cases: 7.8 Severe cases: 8.8	Overall: 56.0 Moderat e cases: 52.0 Severe cases: 61.0	Overall: 19.0 Modera te cases: 30.0 Severe cases: 9.1	NA	NA
Lescure et al ⁴⁸	Paris and Bordea ux	Case- series	Publication: 3/27/20 Study:	5	Patients with laboratory- confirmed 2019-nCoV	2019-nCoV infection was confirmed	47.0 ≤40:	Overall : 26.6	NA	Overall : 47.0	Overall : 40.0	ICU: 60.0 Non-ICU: 40.0	NA

			1/24/20- 1/29/20		who admitted into Bichat- Claude Bernard University Hospital and Pellegrin University Hospital.	by real- time RT- PCR.							
Zhang et al ⁴⁹	Tianjin	Case- series	Publication: 3/29/20 Study: 2/3/20- 2/17/20	3	Children with laboratory- confirmed 2019-nCoV were enrolled from The Children's Hospital of Tianjin.	2019-nCoV infection was confirmed by real- time RT- PCR.	Overall: 26.0	Overall: 21.7	NA	Overall: 7.7	Overall: 0	NA	NA
Easom et al ⁵⁰	United Kingdo m	Case- series	Publication: 3/29/20 Study: 1/29/20- 2/24/20	20	Patients with laboratory- confirmed 2019-nCoV, aged 0-76 years, were enrolled from Regional infectious unit in the UK.	2019-nCoV infection was confirmed by real- time RT- PCR.	NA	Elevated ALT: 10%	NA	Overall: 42.5	Overall: 52.9	NA	NA
Wang et al ⁵¹	Wuhan	Case- series	Publication: 3/30/20 Study: 1/1/20- 2/6/20	339	Elderly patients with laboratory- confirmed 2019-nCoV were enrolled from Renmin	2019-nCoV infection was confirmed by real- time RT- PCR.	Overall: 32.0 Abnorm al liver function: 28.3%	Overall: 27.0 Abnorm al liver function: 28.3%	NA	Overall: 69.0	Overall: 51.0	NA	Overall: 0.6

Bhatraj u et al ⁵²	Seattle	Case- series	Publication: 3/30/20 Study: 1/19/20- 3/9/20	24	Hospital of Wuhan University, who were followed until 3/5/20. Patients aged ≥ 18 years with laboratory- confirmed 2019-nCoV were enrolled from the nine hospital	2019-nCoV infection was confirmed by real- time RT- PCR.	<40: 59.0% >40: 41.0%	≤40: 68.0% >40: 32.0%	Highest bilirubin (mg/dL) level: 0.6	Overall : 64.0 ± 18.0	Overall : 38.0	ICU: 100.0 Non-ICU: 0	NA
Lin et al ⁵³	Zhuhai	Case- series	Publication: 4/2/20 Study: 1/17/20- 2/15/20	95	ICUs Patients with laboratory- confirmed 2019-nCoV were enrolled from the Fifth Affiliated Hospital of Sun Yat-sen University.	2019-nCoV infection was confirmed by real- time RT- PCR.	Overall: ≤35 (female) or 40 (male): 95.8% >35 (female) or 40 (male): 4.2%	Overall: ≤40 (female) or 50 (male): 94.7% >40 (female) or 50 (male): 5.3%	Overall: ≤24: 76.8% >24: 23.2%	Overall: 45.3 ± 18.3 GI sympto ms: 48.0 ± 17.1 No GI sympto ms: 41.1 ± 19.5	Overall: 52.6 Gl sympto ms: 53.4 No Gl sympto ms: 51.4	NA	NA
Xie et al ⁵⁴	Wuhan	Case- series	Publication: 4/2/20 Study: 2/2/20- 2/23/20	79	Patients with laboratory- confirmed 2019-nCoV were enrolled from non- ICU ward in Jinyintan hospital.	2019-nCoV infection was confirmed by real- time RT- PCR.	Overall: 30.0 Moderat e pneumo nia: 28.0 Severe pneumo nia: 35.0 Liver injury	Overall: 34.0 Moderat e pneumo nia: 30.0 Severe pneumo nia: 36.5 Liver injury	Overall: 13.6 Moderat e pneumo nia: 13.9 Severe pneumo nia: 12.7 Liver injury	Overall: 60.0 Moderat e pneumo nia: 59.0 Severe pneumo nia: 62.5 Liver injury	Overall: 44.3 Moder ate pneum onia: 49.0 Severe pneum onia: 35.7 Liver injury	ICU: 0 Non-ICU: 100.0	NA

							group: 59.0 No liver injury group: 25.0	group: 74.0 No liver injury group: 23.0	group: 59.0 No liver injury group: 25.0	group: 62.0 No liver injury group: 56.0	group: 27.6 No liver injury group: 55.3		
Zhang et al ⁵⁵	Wuhan	Case- control study	Publication: 4/2/20 Study: 1/18/20- 2/22/20	229 (115 cases with positive 2019- nCoV and 114 controls with comminut y- acquired pneumoni a)	Cases were laboratory- confirmed 2019-nCoV- infected pneumonia enrolled from Zhongnan hospital of Wuhan University. Control were patients with community- acquired pneumonia admitted at the same hospital from 1/22/20- 2/22/20.	2019-nCoV infection was confirmed by RT-PCR.	25.0 Case Overall: 28.3 ≤40: 85.2% 40-120: 14.8% >120: 0% Mild group: 24.4 ≤40: 94.0% 40-120: 6.0% >120: 0% Severe group: 64.6 ≤40: 61.3% 40-120: 38.7% >120: 0% ICU: 41.0 Control Overall: 33.7 ≤40: 78.1%	23.0 Case Overall: 25.7 ≤50: 90.4% 50-150: 8.7% >150: 0.9% Mild group: 21.2 ≤50: 96.4% 50-150: 3.6% >150: 0% Severe group: 37.9 ≤50: 74.2% 50-150: 22.6% >150: 3.2% ICU: 32.1 Control Overall: 26.3	25.0 Case Overall: 11.3 ≤21: 93.9% 21-31.5: 6.1% Mild group: 10.3 ≤21: 96.4% 21-31.5: 3.6% >31.5: 0% Severe group: 14.1 ≤21: 83.9% 21-31.5: 12.9% >31.5: 3.2% ICU: 17.0 Control: 12.7 ≤21: 96.4%	56.0 Case Overall: 49.5 Mild group: 44.0 Severe group: 64.6 Control Overall: 61.1	55.3 Case Overall: 57.4 Mild group: 65.5 Severe group: 35.5 Control Overall: 51.8	Case ICU: 6.1% Non-ICU: 93.9%	NA
							40-120: 19.3% >120: 2.6%	≤50: 88.6% 50-150: 11.4%	21-31.5: 3.6				

								>150: 0%					
Han et al ⁵⁶	Shaanxi	Case- series	Publication: 4/6/20 Study: 1/31/20- 2/16/20	32	Adult and pediatric patients with laboratory- confirmed 2019-nCoV infection were enrolled from Xian Eighth hospital.	2019-nCoV infection was confirmed by clinical and real time RT- PCR.	Adult ≤40: 80.0% >40: 20.0% Children ≤50: 57.1% >50: 42.9%	Adult ≤50: 84.0% >50: 16.0% Children ≤37: 85.7% >37: 14.3%	Adult ≤17.1: 72.0% >17.1: 28.0% Children ≤34.2: 85.7% >34.2: 14.3%	Adults: 44.0 Children: 1.3	Adult: 52.0 Childre n: 42.9	General inpatient: 100.0	NA
Fu et al ⁵⁷	China	Case- series	Publication: 4/6/20	350	Patients with laboratory- confirmed 2019-nCoV infection were enrolled from Union Hospital of Huazhong University of Science and Technology and Second People's Hospital of Fuyang City.	2019-nCoV infection was confirmed by real time RT-PCR.	Overall: 24.0 Elevated AST: 19.5% Non- severe: 26.0 Severe: 29.0 Critical ill: 49.0	Overall: 23.0 Elevated ALT: 19.5% Non- severe: 22.0 Severe: 23.0 Critical ill: 33.0 Liver disease: 24.5 Without liver disease: 23.0	Non- severe: 10.4 Severe: 10.9 Critical ill: 12.6	NA	Overall: 46.5	NA	Overall: 4.7
Tian et al ⁵⁸	Jilin	Case- series	Publication: 4/7/20 Study: 1/21/20- 3/5/20	59	Pediatric and adult patients with laboratory- confirmed 2019-nCoV	2019-nCoV infection was confirmed by real time RT-PCR.	Overall: 25.0 ≤40: 83.7 >40: 16.3%	25.0 Overall: 25.0 Male ≤50: 83.7 >50: 16.3% Female	Overall: 7.9 ≤23: 98.0% >23: 2.0%	Overall: 41.0	Overall: 42.4	NA	NA

					infection were enrolled from three tertiary hospitals in Jilin province			≤40: 76.2 >40: 23.8%					
Ji et al ⁵⁹	China	Case- series	Publication: 4/8/20 Study: 1/20/20- 2/18/20	202	Patients with laboratory- confirmed 2019-nCoV infection who were tested for NAFLD were enrolled from two hospitals in China.	2019-nCoV infection was confirmed by RT-PCR.	Elevated AST: 16.8%	Elevated ALT: 50.0%	Elevated total bilirubin: 8.4%	Overall: 44.5	Overall: 44.1	NA	NAFLD: 37.6 Hepatitis B: 3.5
Lei et al ⁶⁰	Wuhan	Case- series	Publication: 4/9/20 Study: 1/22/20- 2/12/20	20	Patients with laboratory- confirmed 2019-nCoV infection were enrolled from the Third Affiliated Hospital of Sun Yat-Sen University.	2019-nCoV infection was confirmed by real time RT-PCR.	Elevated AST: 15.0%	Elevated ALT: 20.0%	Elevated total bilirubin: 5.0%	Overall: 43.2	Overall: 50.0	ICU: 23.0 Non-ICU: 77.0	Digestive system disease: 15.0
Qian et al ⁶¹	Shangh ai	Case- series	Publication: 4/9/20 Study: 1/20/20- 2/24/20	324	Patients with laboratory- confirmed 2019-nCoV- infected pneumonia were enrolled from	2019-nCoV infection was confirmed by real time RT-PCR.	Overall: 29.3 Combine d AST and ALT elevatio n: 10.5% Mild	Overall: 27.9 ≤40: 84.3% >40: 15.7% Mild group: 21.5	Overall: 9.5 ≤17.1: 93.5% >17.1: 6.5% Mild group: 8.0	Overall: 51.0 Mild group: 48.5 Severe group: 65.0	Overall: 48.5 Mild group: 50.7 Severe group: 23.1	NA	Hepatitis B Overall: 6.2 Mild group: 6.0 Severe group: 7.7 Fatty liver:

					Shanghai Public Health Clinical Center.		group: 23.0 Severe group: 34.0	Severe group: 26.0	Severe group: 10.8				Overall: 21.6 Mild group: 20.5 Severe group: 34.6
Cholank eril et al ⁶²	Californ ia	Case- series	Publication: 4/10/20 Study: 3/4/20- 3/24/20	65	Patients with laboratory- confirmed 2019-nCoV infection were enrolled from Standford Hospital.	2019-nCoV infection was confirmed by RT-PCR.	Overall: 35.0	Overall: 32.0	Overall: 0.4 mg/dl	Overall: 50.0	Overall: 46.6	ICU: 7.8% General inpatient: 20.7% Outpatient : 71.6%	Overall: 2.8
Petrilli et al ⁶³	New York City	Case- series	Publication: 4/11/20 Study: 3/1/20- 4/2/20	1,582	Hospitalized and outpatient patients with laboratory- confirmed 2019-nCoV infection were enrolled from New York University Langone Health and were followed up until 4/7/20.	2019-nCoV infection was confirmed by real time RT-PCR.	Non- critical: 39.0 Critical: 52.0	Non- critical: 32.0 Critical: 35.0	NA	General inpatient : 62.0 Outpatie nt: 41.0	General inpatie nt: 37.4 Outpati ent: 61.0	ICU: 15.8 General inpatient: 32.9 Outpatient : 51.3	NA
Cai et al ⁶⁴	Shenzh en	Case- series	Publication: 4/14/20 Study: 1/11/20- 2/21/20	417	Patients with laboratory- confirmed 2019-nCoV infection were	2019-nCoV infection was confirmed by real time RT-PCR.	Overall: 26.5 Abnorm al liver function: 34.0	Overall: 21.0 Abnorm al liver function: 27.0	Overall: 10.9 Abnorm al liver function: 16.8	Overall: 47.0 Abnorm al liver function: 47.0	Overall: 52.5 Abnor mal liver	NA	Overall: 5.0 Abnormal liver function: 8.2

enrolled	Liver	Liver	Liver	Liver	functio	Liver
from the	injury:	injury:	injury:	injury:	n: 39.8	injury: 14.3
Third	47.2	47.0	17.2	53.0	Liver	
People's	≤40:	≤40:	≤17.1:		injury:	
Hospital of	81.8%	87.1%	76.8%		33.3	
Shenzhen.	41-80:	41-80:	17.2-			
	16.5%	11.5%	34.2:			
	81-120:	81-120:	21.7%			
	1.4%	1.2%	34.3-			
	>120:	>120:	51.3:			
	0.2%	0.2%	1.2%			
			>51.3:			
			0.2%			

Abbreviation: ALP; alkaline phosphatase, ALT; alanine aminotransferase, AST; aspartate aminotransferase, CT; computed tomography, GGT; gammy glutamyl transferase, ICU; intensive care unit, NA; not applicable, NAFLD; nonalcoholic fatty liver disease, NCIP; novel coronavirus-infected pneumonia, nCoV; new corona virus, RT-PCR; real-time polymerase chain reaction, SARS-CoV2; Severe acute respiratory syndrome coronavirus 2

Data are mean (SD) or median (IQR) or n/N (%), where N is the total number of patients with available data.

References

- 1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-506.
- 2. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet.* 2020;395(10223):507-513.
- 3. Chen L, Liu HG, Liu W, et al. [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]. *Zhonghua Jie He He Hu Xi Za Zhi*. 2020;43(3):203-208.
- 4. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*. 2020.
- 5. Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. *Sci China Life Sci.* 2020;63(3):364-374.
- 6. Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. *Lancet.* 2020;395(10226):809-815.
- 7. Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. *Bmj.* 2020;368:m606.
- 8. Yao N, Wang SN, Lian JQ, et al. [Clinical characteristics and influencing factors of patients with novel coronavirus pneumonia combined with liver injury in Shaanxi region]. *Zhonghua Gan Zang Bing Za Zhi.* 2020;28(0):E003.
- 9. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study. *Lancet Respir Med.* 2020.
- 10. lei l, Jian-ya G. Clinical characteristics of 51 patients discharged from hospital with COVID-19 in Chongqing, China. *medRxiv*. 2020:2020.2002.2020.20025536.
- 11. Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. *Lancet Infect Dis.* 2020;20(4):425-434.
- 12. Cao W. Clinical features and laboratory inspection of novel coronavirus pneumonia (COVID-19) in Xiangyang, Hubei. *medRxiv.* 2020:2020.2002.2023.20026963.
- 13. Yang W, Cao Q, Qin L, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): A multicenter study in Wenzhou city, Zhejiang, China. J Infect. 2020;80(4):388-393.
- 14. Huang Y, Tu M, Wang S, et al. Clinical characteristics of laboratory confirmed positive cases of SARS-CoV-2 infection in Wuhan, China: A retrospective single center analysis. *Travel Med Infect Dis.* 2020:101606.
- 15. Fan Z, Chen L, Li J, et al. Clinical Features of COVID-19-Related Liver Damage. *Clin Gastroenterol Hepatol.* 2020.
- 16. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*. 2020.
- 17. Liu W, Tao ZW, Lei W, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. *Chin Med J (Engl).* 2020.

- 18. Wu J, Liu J, Zhao X, et al. Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study. *Clin Infect Dis.* 2020.
- 19. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. *Lancet Gastroenterol Hepatol.* 2020.
- 20. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020;395(10229):1054-1062.
- 21. Li L, Li S, Xu M, et al. Risk factors related to hepatic injury in patients with corona virus disease 2019. *medRxiv*. 2020:2020.2002.2028.20028514.
- 22. Zhao D, Yao F, Wang L, et al. A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias. *Clin Infect Dis.* 2020.
- 23. Zhou Z, Zhao N, Shu Y, Han S, Chen B, Shu X. Effect of gastrointestinal symptoms on patients infected with COVID-19. *Gastroenterology*. 2020.
- 24. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med.* 2020.
- 25. Zhu W, Xie K, Lu H, Xu L, Zhou S, Fang S. Initial clinical features of suspected coronavirus disease 2019 in two emergency departments outside of Hubei, China. *J Med Virol.* 2020.
- 26. Lo IL, Lio CF, Cheong HH, et al. Evaluation of SARS-CoV-2 RNA shedding in clinical specimens and clinical characteristics of 10 patients with COVID-19 in Macau. *Int J Biol Sci.* 2020;16(10):1698-1707.
- 27. Mo P, Xing Y, Xiao Y, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. *Clin Infect Dis.* 2020.
- 28. Gao Y, Li T, Han M, et al. Diagnostic Utility of Clinical Laboratory Data Determinations for Patients with the Severe COVID-19. *J Med Virol.* 2020.
- 29. Jin X, Lian JS, Hu JH, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. *Gut.* 2020.
- 30. Qian GQ, Yang NB, Ding F, et al. Epidemiologic and Clinical Characteristics of 91 Hospitalized Patients with COVID-19 in Zhejiang, China: A retrospective, multi-centre case series. *Qjm.* 2020.
- 31. Luo S, Zhang X, Xu H. Don't overlook digestive symptoms in patients with 2019 novel coronavirus disease (COVID-19). *Clin Gastroenterol Hepatol.* 2020.
- 32. Pan L, Mu M, Ren HG, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, crosssectional, multicenter study. *Am J Gastroenterol.* 2020.
- 33. Wan S, Xiang Y, Fang W, et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. *J Med Virol.* 2020.
- 34. Arentz M, Yim E, Klaff L, et al. Characteristics and Outcomes of 21 Critically III Patients With COVID-19 in Washington State. *Jama*. 2020.
- 35. Chen J, Qi T, Liu L, et al. Clinical progression of patients with COVID-19 in Shanghai, China. J Infect. 2020.
- 36. Su L, Ma X, Yu H, et al. The different clinical characteristics of corona virus disease cases between children and their families in China the character of children with COVID-19. *Emerg Microbes Infect.* 2020;9(1):707-713.
- 37. Ye G, Pan Z, Pan Y, et al. Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation. *J Infect.* 2020.

- 38. Zhang X, Cai H, Hu J, et al. Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings. *Int J Infect Dis.* 2020.
- 39. Deng Y, Liu W, Liu K, et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study. *Chin Med J (Engl).* 2020.
- 40. Zhou B, She J, Wang Y, Ma X. The Clinical Characteristics of Myocardial injury 1 in Severe and Very Severe Patients with 2019 Novel Coronavirus Disease. *J Infect.* 2020.
- 41. Tang X, Du R, Wang R, et al. Comparison of Hospitalized Patients with Acute Respiratory Distress Syndrome Caused by COVID-19 and H1N1. *Chest.* 2020.
- 42. Lian J, Jin X, Hao S, et al. Analysis of Epidemiological and Clinical features in older patients with Corona Virus Disease 2019 (COVID-19) out of Wuhan. *Clin Infect Dis.* 2020.
- 43. Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. *JAMA Cardiol.* 2020.
- 44. Zheng F, Liao C, Fan QH, et al. Clinical Characteristics of Children with Coronavirus Disease 2019 in Hubei, China. *Curr Med Sci.* 2020.
- 45. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ*. 2020;368:m1091.
- 46. Zhang G, Zhang J, Wang B, Zhu X, Wang Q, Qiu S. Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis. *Respir Res.* 2020;21(1):74.
- 47. Chen G, Wu D, Guo W, et al. Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. *J Clin Invest.* 2020.
- 48. Lescure FX, Bouadma L, Nguyen D, et al. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. *Lancet Infect Dis.* 2020.
- 49. Zhang T, Cui X, Zhao X, et al. Detectable SARS-CoV-2 Viral RNA in Feces of Three Children during Recovery Period of COVID-19 Pneumonia. *J Med Virol.* 2020.
- 50. Easom N, Moss P, Barlow G, et al. Sixty-eight consecutive patients assessed for COVID-19 infection: Experience from a UK Regional infectious diseases Unit. *Influenza Other Respir Viruses*. 2020.
- 51. Wang L, He W, Yu X, et al. Coronavirus Disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week followup. J Infect. 2020.
- 52. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in Critically III Patients in the Seattle Region Case Series. *N Engl J Med.* 2020.
- 53. Lin L, Jiang X, Zhang Z, et al. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. *Gut.* 2020.
- 54. Xie H, Zhao J, Lian N, Lin S, Xie Q, Zhuo H. Clinical characteristics of Non-ICU hospitalized patients with coronavirus disease 2019 and liver injury : A Retrospective study. *Liver Int.* 2020.
- 55. Zhang Y, Zheng L, Liu L, Zhao M, Xiao J, Zhao Q. Liver impairment in COVID-19 patients: a retrospective analysis of 115 cases from a single center in Wuhan city, China. *Liver Int.* 2020.
- 56. Han YN, Feng ZW, Sun LN, et al. A comparative-descriptive analysis of clinical characteristics in 2019-Coronavirus-infected children and adults. *J Med Virol.* 2020.

- 57. Fu L, Fei J, Xu S, et al. Acute liver injury and its association with death risk of patients with COVID-19: a hospital-based prospective casecohort study. *medRxiv*. 2020:2020.2004.2002.20050997.
- 58. Tian S, Zhu X, Sun X, et al. Longitudinal analysis of laboratory findings during the process of recovery for patients with COVID-19. *medRxiv*. 2020:2020.2004.20053280.
- 59. Ji D, Qin E, Xu J, et al. Implication of non-alcoholic fatty liver diseases (NAFLD) in patients with COVID-19: a preliminary analysis. *J Hepatol.* 2020.
- 60. Lei Z, Cao H, Jie Y, et al. A cross-sectional comparison of epidemiological and clinical features of patients with coronavirus disease (COVID-19) in Wuhan and outside Wuhan, China. *Travel Med Infect Dis.* 2020:101664.
- 61. Qian ZP, Mei X, Zhang YY, et al. [Analysis of baseline liver biochemical parameters in 324 cases with novel coronavirus pneumonia in Shanghai area]. *Zhonghua Gan Zang Bing Za Zhi.* 2020;28(0):E005.
- 62. Cholankeril G, Podboy A, Aivaliotis VI, et al. High Prevalence of Concurrent Gastrointestinal Manifestations in Patients with SARS-CoV-2: Early Experience from California. *Gastroenterology*. 2020.
- 63. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City. *medRxiv*. 2020:2020.2004.2008.20057794.
- 64. Cai Q, Huang D, Yu H, et al. Characteristics of Liver Tests in COVID-19 Patients. *J Hepatol.* 2020.